DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo

GlaxoSmithKline (NYSE: GSK)

48.60 -1.48 (-2.96%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GSK $48.60 -2.96%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $48.91
Previous Close $50.08
Daily Range $48.23 - $48.98
52-Week Range $48.23 - $56.73
Market Cap $116.7B
P/E Ratio 17.21
Dividend (Yield) $2.56 (5.3%)
Ex-Dividend Date
Dividend Pay Date
08/06/14
10/02/14
Volume 10,705,900
Average Daily Volume 2,575,147
Current FY EPS $3.41

Sector

Healthcare

Industry

Drugs

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

News & Commentary Rss Feed

After Market: Another Super Tuesday for Stocks

GlaxoSmithKline Declines on Corruption Investigation as European ADRs Drop on Lower German Confidenc

GlaxoSmithKline Declines on Corruption Investigation as European ADRs Drop on Lower German Confidence Data

GlaxoSmithKline (GSK) Weak In Early Morning Trading

Pre-Market: Amazon Expects Major Third-Quarter Loss; Durable Goods Rise In June

Plus: BSkyB will acquire Italian and German assets from 21st Century Fox for $8.3 billion.

Pre-Market Most Active for Jul 25, 2014 : NOK, RFMD, GSK, FB, P, AMZN, GSJK, BIDU, QQQ, TWTR, RBS,

Pre-Market Most Active for Jul 25, 2014 : NOK, RFMD, GSK, FB, P, AMZN, GSJK, BIDU, QQQ, TWTR, RBS, ALU

UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog

Glaxo (GSK) Slips on Disappointing Q2 Earnings, Cuts View - Analyst Blog

Pre-Market Most Active for Jul 24, 2014 : FB, NOK, F, AAL, GSK, ANGI, GOV, ALU, GM, QCOM, ARIA, AAP

Pre-Market Most Active for Jul 24, 2014 : FB, NOK, F, AAL, GSK, ANGI, GOV, ALU, GM, QCOM, ARIA, AAPL

Jim Cramer's 'Mad Money' Recap: Unconventional Wisdom

Is Inovio Undervalued After Positive HPV Therapy Results?

GlaxoSmithKline's (GSK) CEO Andrew Wittyon Q2 2014 Results - Earnings Call Transcript

See More GSK News...

GSK's Top Competitors

GSK $48.60 (-2.96%)
Current stock: GSK
JNJ $102.11 (-0.09%)
Current stock: JNJ
NVS $88.41 (-0.81%)
Current stock: NVS
RHHBY $36.91 (-0.90%)
Current stock: RHHBY